公开(公告)号：US20240327486A1

公开(公告)日：2024-10-03

申请号：US18627761

申请日：2024-04-05

Applicant: Amgen Inc.

Inventor： Eric Alan BUTZ ,  Christy Ann THOMSON ,  Marc Alain GAVIN ,  Ian Nevin FOLTZ ,  Dong XIA ,  Dina N. ALCORN ,  Randal Robert KETCHEM ,  Ai Ching LIM ,  Kathy MANCHULENKO ,  Laura SEKIROV ,  Kelly Ann BERRY ,  Cyr Clovis Chua DE IMUS ,  Neeraj Jagdish AGRAWAL ,  Gunasekaran KANNAN ,  Li LI

IPC: C07K14/55 ,  A61K38/20 ,  A61P37/00 ,  C07K16/24

CPC classification number: C07K14/55 ,  A61K38/2013 ,  A61P37/00 ,  C07K16/246 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20210139554A1

公开(公告)日：2021-05-13

申请号：US17065395

申请日：2020-10-07

Applicant: Amgen Inc.

Inventor： Eric Alan BUTZ ,  Christy Ann THOMSON ,  Marc Alain GAVIN ,  Ian Nevin FOLTZ ,  Dong XIA ,  Dina N. ALCORN ,  Randal Robert KETCHEM ,  Ai Ching LIM ,  Kathy MANCHULENKO ,  Laura SEKIROV ,  Kelly Ann BERRY ,  Cyr Clovis Chua DE IMUS ,  Neeraj Jagdish AGRAWAL ,  Gunasekaran KANNAN ,  Li LI

IPC: C07K14/55 ,  A61P37/00 ,  A61K38/20 ,  C07K16/24

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20190127452A1

公开(公告)日：2019-05-02

申请号：US16099986

申请日：2017-05-11

Applicant: AMGEN INC.

Inventor： Randal Robert KETCHEM ,  Jeffrey T. MCGREW ,  Dina A. FOMINA YADLIN ,  Trent P. MUNRO ,  Neeraj Jagdish AGRAWAL ,  Kristine M. DARIS

IPC: C07K16/18 ,  C12N15/67 ,  C12N15/65 ,  C12N15/85 ,  C07K16/06

Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.